Credit score: Unsplash/CC0 Public Area
The GLP-1 drug, exenatide, has no constructive impression on the motion, signs or mind imaging of individuals with Parkinson’s, finds a brand new research led by UCL researchers.
For his or her analysis, printed in The Lancet, the staff designed a randomized managed Part II trial to definitively decide whether or not exenatide use was related to any profit in folks with Parkinson’s and if it led to a slower fee of development of the sickness, after smaller research had steered the drug could also be useful. The research is the world’s largest and longest trial of exenatide in folks with Parkinson’s illness.
A complete of 194 folks with Parkinson’s illness participated within the trial throughout six analysis hospitals within the UK, together with in London, Oxford, Plymouth, Salford and Edinburgh. They both used exenatide injections on a weekly foundation, or a visually equivalent placebo.
The trial ran for 96 weeks and was double blind, that means that neither the members nor researchers knew who was receiving the true remedy or placebo.
On the finish of the research interval, the researchers discovered that there was no benefit at any level over the course of 96 weeks within the group utilizing exenatide. And no advantages have been proven within the goal examination of sufferers’ actions, their very own studies of symptom severity, or imaging findings.
Lead creator, Professor Thomas Foltynie (UCL Queen Sq. Institute of Neurology) mentioned, “The results of this trial have been eagerly anticipated and the negative results will be a major disappointment to patients affected by Parkinson’s disease and the Parkinson’s disease research community.”
GLP-1 medication—corresponding to semaglutide (Wegovy) and Ozempic—have change into more and more widespread over current years and there was an unlimited curiosity of their potential well being advantages.
For instance, semaglutide (Wegovy) can be utilized as a remedy for kind 2 diabetes alongside being a licensed weight reduction drug.
In the meantime, older members of the drug class—corresponding to exenatide and lixisenatide—have additionally been proven to be able to penetrating into the mind and former small trials have steered potential advantages to folks with Parkinson’s illness.
Professor Foltynie added, “It is not yet clear whether there may be a subgroup of people with Parkinson’s disease who may get benefit from the use of exenatide. We will continue to scrutinize the data to see whether abnormal blood test results such as having ‘pre-diabetes’ might predict a better response to exenatide, and whether there were more of these people in the earlier, smaller trials in which we found positive overall effects.”
The trial occurred on the UCL Queen Sq. Institute of Neurology and the UCLH Nationwide Hospital for Neurology and Neurosurgery.
There was a excessive degree of participant retention all through the trial and the analysis staff have confirmed excessive ranges of compliance with the treatment by means of blood exams checking the degrees of exenatide, so there is usually a excessive degree of confidence within the outcomes.
Extra info:
Exenatide as soon as every week versus placebo as a possible illness modifying remedy for folks with Parkinson’s illness within the UK: a part 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial, The Lancet (2025). DOI: 10.1016/S0140-6736(24)02808-3
Supplied by
College Faculty London
Quotation:
GLP-1 drug reveals little profit for folks with Parkinson’s illness, trial finds (2025, February 4)
retrieved 4 February 2025
from https://medicalxpress.com/information/2025-02-glp-drug-benefit-people-parkinson.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
